713P Pembrolizumab (Pembro) vs placebo (Pbo) as second-line treatment for sorafenib-treated advanced hepatocellular carcinoma (aHCC): 4.5-year follow-up from KEYNOTE-240

Autor:	J. Edeline, R.S. Finn, M. Bouattour, A-L. Cheng, S.L. Chan, T. Yau, M. Garrido, J. Knox, B. Daniele, V. Breder, H.Y. Lim, S. Ogasawara, A. Odeleye-Ajakaye, I. Martinez-Forero, A.B. Siegel, P. Merle
Rok vydání:	2022
Předmět:	Oncology Hematology
Zdroj:	Annals of Oncology. 33:S868-S869
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9070226f09c48f5289ae3c4d347a0baf https://doi.org/10.1016/j.annonc.2022.07.837 Zobrazit plný text záznamu